We are live on ! Find out more
TCM

TCG Crossover Management Portfolio holdings

AUM $4.16B
1-Year Est. Return 983.43%
This Fund
S&P 500
This Quarter Est. Return
+22.55%
1 Year Est. Return
+983.43%
3 Year Est. Return
+3,012.95%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$679M
AUM Growth
+$69.3M
Cap. Flow
+$84.1M
Cap. Flow %
12.38%
Top 10 Hldgs %
61.79%
Holding
30
New
8
Increased
3
Reduced
2
Closed
4

Top Buys

Rank Stock Value
1
GPCR icon
Structure Therapeutics
GPCR
+$37.1M
2
INBX
Inhibrx, Inc. Common Stock
INBX
+$36.6M
3
SVRA icon
Savara
SVRA
+$35.7M
4
CMPS
Compass Pathways
CMPS
+$34.2M
5
TSHA icon
Taysha Gene Therapies
TSHA
+$20.8M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$96.3M
2
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$52.9M
3
IMVT icon
Immunovant
IMVT
+$7.23M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$5.49M
5
ALPN
Alpine Immune Sciences Inc
ALPN
+$2.6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GPCR icon
1
Structure Therapeutics
GPCR
$3.38B
$75.8M 11.16%
1,502,747
+1,152,747
+329% +$37.1M
COGT icon
2
Cogent Biosciences
COGT
$6.02B
$54.9M 8.08%
5,631,042
– –
GERN icon
3
Geron
GERN
$970M
$49.6M 7.3%
23,375,839
-213,940
-0.9% -$581K
ANTX icon
4
AN2 Therapeutics
ANTX
$211M
$43.1M 6.34%
2,678,209
+1,388,889
+108% +$15.7M
SVRA icon
5
Savara
SVRA
$1.08B
$37.8M 5.57%
+10,000,000
New +$35.7M
TSHA icon
6
Taysha Gene Therapies
TSHA
$1.88B
$35.1M 5.17%
+11,111,111
New +$20.8M
KALV
7
DELISTED
KalVista Pharmaceuticals
KALV
$32.7M 4.81%
3,395,495
– –
INBX
8
DELISTED
Inhibrx, Inc. Common Stock
INBX
$32.1M 4.73%
+1,750,387
New +$36.6M
JBIO
9
Jade Biosciences
JBIO
$1.33B
$29.9M 4.4%
62,894
– –
ICVX
10
DELISTED
Icosavax, Inc. Common Stock
ICVX
$28.7M 4.23%
3,703,704
– –
CMPS
11
Compass Pathways
CMPS
$1.9B
$28.5M 4.2%
+3,858,000
New +$34.2M
VTYX
12
DELISTED
Ventyx Biosciences
VTYX
$28.3M 4.17%
815,724
– –
TYRA icon
13
Tyra Biosciences
TYRA
$1.49B
$27.4M 4.03%
1,989,103
– –
MDGL icon
14
Madrigal Pharmaceuticals
MDGL
$12.3B
$26.3M 3.87%
179,917
+30,000
+20% +$5.65M
SLN
15
Silence Therapeutics
SLN
$834M
$20.7M 3.04%
2,104,875
– –
TARS icon
16
Tarsus Pharmaceuticals
TARS
$3.15B
$20.3M 2.99%
+1,142,857
New +$20.2M
RYZB
17
DELISTED
RayzeBio, Inc. Common Stock
RYZB
$19.3M 2.84%
+869,908
New +$18.3M
DYN icon
18
Dyne Therapeutics
DYN
$4.68B
$14.8M 2.18%
1,650,150
– –
CNTA
19
DELISTED
Centessa Pharmaceuticals
CNTA
$13.2M 1.94%
+2,040,816
New +$14M
KURA icon
20
Kura Oncology
KURA
$1.13B
$13M 1.91%
1,423,642
– –
IMVT icon
21
Immunovant
IMVT
$8.51B
$12.9M 1.89%
334,853
-320,000
-49% -$7.23M
TRDA icon
22
Entrada Therapeutics
TRDA
$273M
$9.24M 1.36%
584,955
– –
GRCL
23
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$8.75M 1.29%
+3,038,889
New +$11.1M
CABA icon
24
Cabaletta Bio
CABA
$529M
$7.41M 1.09%
486,795
– –
MRUS
25
DELISTED
Merus
MRUS
$7.07M 1.04%
300,000
– –
1
2

Similar funds

GCM
Gates Capital Management New York $4.16B AUM 21% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
CIC
Chilton Investment Company Stamford, Connecticut $4.17B AUM 1.75% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $4.15B AUM 31.06% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $4.15B AUM
CAM
Crake Asset Management London, United Kingdom $4.18B AUM 13.97% 1-Year Est. Return
JFG
JMG Financial Group Downers Grove, Illinois $4.14B AUM 21.49% 1-Year Est. Return

TCG Crossover Management's Q3 2023 Portfolio in Review

As of Q3 2023, TCG Crossover Management held 30 positions worth $679M, up 11% from $610M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

TCG Crossover Management deployed $84.1M of net new capital in Q3 2023, opening 8 new positions and adding to 3 existing holdings. Its largest new stake was Inhibrx, Inc. Common Stock: 1,750,387 shares worth $32.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Immunovant, an estimated $7.23M trimmed.

  • TCG Crossover Management's largest Q3 2023 buy was Inhibrx, Inc. Common Stock: 1,750,387 shares worth $32.1M.
  • TCG Crossover Management added most to Structure Therapeutics in Q3 2023, an estimated $37.1M increase.
  • TCG Crossover Management's biggest Q3 2023 reduction was Immunovant, cutting an estimated $7.23M.
  • TCG Crossover Management fully exited IVERIC bio, Inc. Common Stock in Q3 2023, selling an estimated $96.3M.
  • TCG Crossover Management's ten largest holdings make up 62% of its $679M portfolio in Q3 2023.
  • TCG Crossover Management opened 8 new positions and closed 4 in Q3 2023.
  • TCG Crossover Management's portfolio value rose 11% quarter-over-quarter to $679M.

Based on TCG Crossover Management's 13F filing for Q3 2023, filed 14 Nov 2023.